439 related articles for article (PubMed ID: 32866938)
1. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.
Mangone G; Bekadar S; Cormier-Dequaire F; Tahiri K; Welaratne A; Czernecki V; Pineau F; Karachi C; Castrioto A; Durif F; Tranchant C; Devos D; Thobois S; Meissner WG; Navarro MS; Cornu P; Lesage S; Brice A; Welter ML; Corvol JC;
Parkinsonism Relat Disord; 2020 Jul; 76():56-62. PubMed ID: 32866938
[TBL] [Abstract][Full Text] [Related]
2. Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson's disease.
Prendes Fernández P; Blázquez Estrada M; Sol Álvarez J; Álvarez Martínez V; Suárez San Martín E; García Fernández C; Álvarez Carriles JC; Lozano Aragoneses B; Saiz Ayala A; Santamarta Liébana E; González Álvarez L
Parkinsonism Relat Disord; 2023 Feb; 107():105282. PubMed ID: 36657280
[TBL] [Abstract][Full Text] [Related]
3. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers.
Pal G; Mangone G; Hill EJ; Ouyang B; Liu Y; Lythe V; Ehrlich D; Saunders-Pullman R; Shanker V; Bressman S; Alcalay RN; Garcia P; Marder KS; Aasly J; Mouradian MM; Link S; Rosenbaum M; Anderson S; Bernard B; Wilson R; Stebbins G; Nichols WC; Welter ML; Sani S; Afshari M; Verhagen L; de Bie RMA; Foltynie T; Hall D; Corvol JC; Goetz CG
Ann Neurol; 2022 Mar; 91(3):424-435. PubMed ID: 34984729
[TBL] [Abstract][Full Text] [Related]
4. Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis.
Artusi CA; Dwivedi AK; Romagnolo A; Pal G; Kauffman M; Mata I; Patel D; Vizcarra JA; Duker A; Marsili L; Cheeran B; Woo D; Contarino MF; Verhagen L; Lopiano L; Espay AJ; Fasano A; Merola A
JAMA Netw Open; 2019 Feb; 2(2):e187800. PubMed ID: 30707228
[TBL] [Abstract][Full Text] [Related]
5. GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.
Lythe V; Athauda D; Foley J; Mencacci NE; Jahanshahi M; Cipolotti L; Hyam J; Zrinzo L; Hariz M; Hardy J; Limousin P; Foltynie T
J Parkinsons Dis; 2017; 7(4):635-644. PubMed ID: 28777757
[TBL] [Abstract][Full Text] [Related]
6. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
[TBL] [Abstract][Full Text] [Related]
7. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
Alcalay RN; Caccappolo E; Mejia-Santana H; Tang M-; Rosado L; Orbe Reilly M; Ruiz D; Ross B; Verbitsky M; Kisselev S; Louis E; Comella C; Colcher A; Jennings D; Nance M; Bressman S; Scott WK; Tanner C; Mickel S; Andrews H; Waters C; Fahn S; Cote L; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Payami H; Molho E; Factor S; Ottman R; Clark LN; Marder K
Neurology; 2012 May; 78(18):1434-40. PubMed ID: 22442429
[TBL] [Abstract][Full Text] [Related]
8. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
[TBL] [Abstract][Full Text] [Related]
9. Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease.
Gruber D; Calmbach L; Kühn AA; Krause P; Kopp UA; Schneider GH; Kupsch A
J Neural Transm (Vienna); 2019 Mar; 126(3):309-318. PubMed ID: 30684055
[TBL] [Abstract][Full Text] [Related]
10. Cognitive predictors of cognitive change following bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease.
Yágüez L; Costello A; Moriarty J; Hulse N; Selway R; Clough C; Samuel M; Ashkan K
J Clin Neurosci; 2014 Mar; 21(3):445-50. PubMed ID: 24231557
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
[TBL] [Abstract][Full Text] [Related]
12. Caregiver burden worsens in the second year after subthalamic nucleus deep brain stimulation for Parkinson's disease.
Jackowiak E; Maher AC; Persad C; Kotagal V; Wyant K; Heston A; Patil PG; Chou KL
Parkinsonism Relat Disord; 2020 Sep; 78():4-8. PubMed ID: 32659619
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease.
Boel JA; Odekerken VJ; Schmand BA; Geurtsen GJ; Cath DC; Figee M; van den Munckhof P; de Haan RJ; Schuurman PR; de Bie RM;
Parkinsonism Relat Disord; 2016 Dec; 33():90-95. PubMed ID: 27688200
[TBL] [Abstract][Full Text] [Related]
14. Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinson's disease.
Kim HJ; Jeon BS; Paek SH; Lee KM; Kim JY; Lee JY; Kim HJ; Yun JY; Kim YE; Yang HJ; Ehm G
J Neurol; 2014 Jun; 261(6):1090-6. PubMed ID: 24687897
[TBL] [Abstract][Full Text] [Related]
15. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
[TBL] [Abstract][Full Text] [Related]
16. Anatomical predictors of cognitive decline after subthalamic stimulation in Parkinson's disease.
Planche V; Munsch F; Pereira B; de Schlichting E; Vidal T; Coste J; Morand D; de Chazeron I; Derost P; Debilly B; Llorca PM; Lemaire JJ; Marques A; Durif F
Brain Struct Funct; 2018 Sep; 223(7):3063-3072. PubMed ID: 29736590
[TBL] [Abstract][Full Text] [Related]
17. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease.
Witt K; Daniels C; Krack P; Volkmann J; Pinsker MO; Kloss M; Tronnier V; Schnitzler A; Wojtecki L; Bötzel K; Danek A; Hilker R; Sturm V; Kupsch A; Karner E; Deuschl G
J Neurol Sci; 2011 Nov; 310(1-2):261-6. PubMed ID: 21733529
[TBL] [Abstract][Full Text] [Related]
18. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Speech Change After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Patients: A 2-Year Prospective Study.
Tanaka Y; Tsuboi T; Watanabe H; Nakatsubo D; Maesawa S; Kato S; Kajita Y; Sato M; Oodake R; Hattori M; Yamamoto M; Wakabayashi T; Katsuno M; Sobue G
J Parkinsons Dis; 2020; 10(1):131-140. PubMed ID: 31884493
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
